 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, April 02, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) ( Centogene , we , or the Company ), the essential life science partner for...

CENTOGENE Receives Nasdaq Non-Compliance Notice

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024...

CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

Complete Pre-TCR Deficiency Found to be Very Rare, Partial Form More Common Than ExpectedCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 29, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V. (Nasdaq...

CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCR  Deficiency

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Centogene receives Nasdaq notice of delisting, will request hearing

CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (the Company ), the essential life science partner for data-driven answers in rare...

CENTOGENE Explores Strategic Alternatives

Notice of Delisting Will Not Immediately Result in the Suspension or Delisting of the Company's SecuritiesCAMBRIDGE, Mass. and ROSTOCK, Germanyand BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE...

CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing

Aims to Leverage Diversified Data to Accelerate and De-Risk Drug Discovery and Clinical DevelopmentCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Jan. 25, 2024 (GLOBE NEWSWIRE) -- CENTOGENE N.V...

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

Partners able to claim up to 30% tax reliefCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for...

CENTOGENE Receives French Research Tax Credit Accreditation

Collaboration to accelerate research to determine role of GBA geneCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential...

CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson's Disease Using Multiomics

Centogene says FY revenue is expected to be between &#x20AC;48.5 million &#x20AC;49.0 million...

Centogene says FY revenue is expected to be between &#x20AC;48.5 million &#x20AC;49.0 million

Centogene NV is a commercial-stage company, which focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. It operates through the following segments: Pharmaceutical, Diagnostics, and Corporate. The Pharmaceutical segment provides solutions to pharmaceutical partners, including target discovery, early patient recruitment and identification, epidemiological insights, and biomarker discovery. The Diagnostics segment offers genetic sequencing and diagnostics services to clients, who are typically physicians, laboratories, or hospitals, either directly or through distributors. The Other segment covers COVID-19 testing services to clients. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.

Volume (M)	23,416.00
52-Wk High	$2.52
52-Wk Low	$0.4566

CNTG Centogene NV

About

Feed

News

Sentiment

Fundamentals